Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alogliptin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 20/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alogliptin SCHEMBL121028 | 1.00 | DPP4 (1.00) | DPP4OPRM1OPRK1DPP8 | |
| Alogliptin SCHEMBL29352995 | 1.00 | DPP4 (1.00) | DPP4OPRM1OPRK1DPP8 | |
| Alogliptin SCHEMBL17036596 | 1.00 | DPP4 (1.00) | DPP4OPRM1OPRK1DPP8 | |
| Alogliptin SCHEMBL475872 | 0.99 | DPP4 (0.98) | DPP4OPRM1OPRK1DPP8 | |
| Alogliptin SCHEMBL17781892 | 0.99 | DPP4 (0.98) | DPP4OPRM1OPRK1DPP8 | |
| SCHEMBL23712233 | 0.97 | DPP4 (1.00) | DPP4OPRM1OPRK1DPP8 | |
| SCHEMBL391800 | 0.97 | DPP4 (1.00) | DPP4OPRM1OPRK1DPP8 | |
| SCHEMBL28406504 | 0.95 | DPP4 (0.91) | DPP4OPRM1OPRK1 | |
| Alogliptin SCHEMBL1071798 | 0.94 | DPP4 (0.91) | DPP4OPRM1OPRK1DPP8 | |
| Alogliptin SCHEMBL476232 | 0.93 | DPP4 (0.86) | DPP4OPRM1OPRK1DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115577-A1 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-11 | — | — | US | claimed |
| US-10894787-B2 | Modulators of the GPR119 receptor and the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2021-01-19 | — | — | US | claimed |
| CN-102079743-B | Dipeptidyl peptidase inhibitors | 武田药品工业株式会社 | 2020-08-25 | — | — | CN | claimed |
| CN-102134229-B | Dipeptidyl peptidase inhibitors | 武田药品工业株式会社 | 2020-08-04 | — | — | CN | claimed |
| CN-102134231-B | Dipeptidyl peptidase inhibitors | 武田药品工业株式会社 | 2020-08-04 | — | — | CN | claimed |
| EP-3323818-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2018-05-23 | — | — | EP | claimed |
| EP-2379522-B1 | CRYSTALLINE FORM OF ALOGLIPTIN | SANDOZ AG (CH) | 2018-02-28 | — | — | EP | claimed |
| US-20170073345-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES AND PRE-DIABETES | ALAPATI MOHAN MURALI (IN) | 2017-03-16 | — | — | US | claimed |
| EP-2410855-B1 | PROCESS FOR THE PREPARATION OF ALOGLIPTIN | MAPI PHARMA LTD (IL) | 2016-06-01 | — | — | EP | claimed |
| WO-2016046679-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES AND PRE-DIABETES | MOHAN M ALAPATI (IN) | 2016-03-31 | — | — | WO | claimed |
| EP-2379522-A1 | CRYSTALLINE FORM OF AN ORGANIC COMPOUND | Sandoz AG (CH) | 2011-10-26 | — | — | EP | claimed |
| US-20110014299-A2 | SOLID PREPARATION COMPRISING ALOGLIPTIN AND METFORMIN HYDROCHLORIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-20 | — | — | US | claimed |
| WO-2011005929-A1 | PIPERIDINE DERIVATIVE AND ITS USE FOR THE TREATMENT OF DIABETS AND OBESITY | ARENA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | claimed |
| WO-2010072680-A1 | CRYSTALLINE FORM OF AN ORGANIC COMPOUND | SANDOZ AG (CH) | 2010-07-01 | — | — | WO | claimed |
| US-20100136127-A1 | SOLID PREPARATION COMPRISING ALOGLIPTIN AND METFORMIN HYDROCHLORIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-03 | — | — | US | claimed |
| EP-1586571-B1 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2008-07-16 | — | — | EP | claimed |
| EP-1586571-A1 | Dipeptidyl peptidase inhibitors | Takeda San Diego, Inc. (US) | 2005-10-19 | — | — | EP | claimed |
| WO-2005095381-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-10-13 | — | — | WO | claimed |
| EP-1480914-A1 | METHOD FOR PREVENTING THE UNCONTROLLED GROWTH OF MICROORGANISMS IN WATER | Beta Tec Hopfenprodukte Gmbh (DE) | 2004-12-01 | — | — | EP | claimed |
| WO-2003074431-A1 | METHOD FOR PREVENTING THE UNCONTROLLED GROWTH OF MICROORGANISMS IN WATER | BETA TEC HOPFENPRODUKTE GMBH (DE) | 2003-09-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073345-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES AND PRE-DIABETES | DPP4, SLC5A1, SLC5A2 | DPP4 1/4885OPRM1 1224/4885OPRK1 1227/4885 |
| US-20240115577-A1 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | DPP4, DPP7, ING2 | DPP4 1/4885OPRM1 4836/4885OPRK1 4489/4885 |
| US-10894787-B2 | Modulators of the GPR119 receptor and the treatment of disorders related thereto | GPR119, GLP1R, DPP9 | DPP4 5/4885OPRM1 1209/4885OPRK1 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.